top of page
2025年7月15日
Designed to drive the future of precision medicine, biotechnology company CytoAurora presented its NanoCast Cell Reveal system at Medical Taiwan. The core technology, which already attracted international attention at the MEDICA Start-Up Competition, efficiently captures and analyzes cancer cells from blood samples in a fully automated workflow, the company’s Vice President, Bryan Tang, PhD, explained. After the sample is obtained from the patient, the semiconductor microfluidic chip captures abnormal cells, which are then classified using AI to detect cancer. Finally, the system generates a comprehensive and detailed report of its findings. This approach significantly shortens diagnostic time, greatly boosting efficiency compared to traditional imaging scans such as MRI and CT, the manufacturer states, adding that this not only enables early cancer screening but also allows for real-time monitoring of treatment efficacy, providing patients with more precise, personalized treatment plans. 新聞連結:https://healthcare-in-europe.com/en/news/medical-taiwan-2025-products.html?preview=true
bottom of page